Dosing regimen of reteplase and costeffectiveness.
Hödl
R
R
Kraxner
W
W
Maier
R
R
Klein
W
W
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000925:Anticoagulants / Q000008:administration & dosage*; D001835:Body Weight; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D009203:Myocardial Infarction / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000191:economics; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000191:economics
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D011994:Recombinant Proteins; C087896:reteplase; D010959:Tissue Plasminogen Activator; D000077284:Abciximab